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Abstract
Costs of care in the intensive care unit are a frequent target for concern in the current healthcare 
system. Utilization of critical care services in the United States is increasing and will continue to 
do so. Acute respiratory distress syndrome (ARDS) is a common and important complication of 
critical illness. Patients with ARDS frequently have long hospitalizations and consume a 
significant amount of healthcare resources. Many patients are discharged with functional 
limitations and high susceptibility to new complications which require significant additional 
healthcare resources. There is increasing literature on the cost-effectiveness of the treatment of 
ARDS, and despite its high costs, treatment remains a cost-effective intervention by current 
societal standards. However, when ARDS leads to prolonged mechanical ventilation, treatment 
becomes less cost-effective. Current research seeks to find interventions that lead to reductions in 
duration of mechanical ventilation and ICU lengths of stay. Limited reductions in ICU length of 
stay have benefits for the patient, but they do not lead to significant reductions in overall hospital 
costs. Early discharge to post-acute care facilities can reduce hospital costs but are unlikely to 
decrease costs for an entire episode of illness. Improved effectiveness of communication between 
clinicians and patients or their surrogates could help avoid costly interventions with poor expected 
outcomes.
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Any discussion of healthcare in the 21st century must include a discussion of the costs of 
delivery of care. The intensive care unit (ICU) consumes a significant portion of hospital 
and healthcare costs. In the coming years, the ICU will remain an obvious target for attempts 
at cost reduction, as the number of critical care medicine beds has been increasing in the 
United States. Between 2000 and 2005, this number grew by 6.5% (88,252 to 93,955), and 
accounted for 15.2% (23.2 million) of hospital days, an increase of 10.6%.1 In 2005, critical 
care medicine costs ($81.7 billion) accounted for 4.1% of overall healthcare expenditures 
and 0.66% of gross domestic product. Acute respiratory distress syndrome (ARDS) remains 
common, with an incidence of 78.9 cases per 100,000 person-years, and mortality remains 
high (38.5%).2 Patients with ARDS almost always require mechanical ventilation, and they 
require higher lengths of stay than their non-mechanically ventilated counterparts. ARDS 
patients are at high risk for requiring prolonged mechanical ventilation, thus have a high 
potential to utilize significant healthcare resources.3 But does ARDS cost more than other 
disease process? Here we will review the basics of health economics, discuss the actual costs 
of ARDS compared to other critical illness, and discuss whether the treatment for ARDS is 
cost-effective.
Terminology
In order to fully understand cost information, an appreciation of cost-related terminology is 
critical. Costs refer to any unit of expenditure that is incurred when providing a service. 
There are several types of costs when considering medical care, including direct vs. indirect, 
fixed vs. variable, medical vs. nonmedical, total vs. marginal.4-7 Direct medical costs are 
those costs consumed in the delivery of a health intervention within the health care setting. 
These can be either fixed costs, i.e. costs that are incurred regardless of whether a service is 
provided, or variable costs, i.e. costs that are only generated when care is actually delivered. 
Examples of fixed costs include nursing salaries or overhead costs (utilities, insurance, 
administrative costs, etc.), while variable costs include physician labor, diagnostic testing, or 
medication costs. Direct non-medical costs are those which are incurred by the patient or 
their family that are not related to care provided by the hospital or physicians. These may 
include medical transportation, family lodging, and rehabilitation or in-home care after the 
hospitalization. Indirect costs are often the most difficult to quantify and include lost wages 
or productivity of the patient or family members.8 Marginal costs refer to the additive costs 
of an additional day of hospitalization.7
Simply reporting total costs of an intervention is one approach to cost analysis. However, a 
more worthwhile exercise is examining cost-effectiveness. This compares not only costs 
between interventions, but also the effects of the intervention, i.e. how well does an 
intervention perform with regard to some outcome. Table 1 shows several commonly 
utilized methods of economic evaluations.5,9,10 Cost-minimization analysis refers to a 
simple practice of comparing how much two interventions with the same effectiveness cost. 
The less expensive intervention would be superior. Unfortunately, medicine (and especially 
critical care medicine) rarely compares two interventions with similar efficacy. Cost-benefit 
analysis takes this one step further, and assigns a monetary benefit to the intervention. 
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Therefore, cost-benefit analysis yields a dollar spent for dollar gained result. However, much 
of the benefit in medicine is difficult to monetize, for example, precisely how much is life 
worth when compared to death? Cost-effectiveness analysis instead examines the ratio of the 
cost of an intervention to a unit of outcome, for example, dollars per life-year gained. This is 
an improvement over either cost-minimization and cost-benefit analyses, but does not allow 
one to compare interventions with different outcomes (e.g. mortality and reduction in days 
of mechanical ventilation are not equal). Cost-utility analysis (often used interchangeably 
with cost-effectiveness analysis) improves upon cost-effectiveness by assigning some 
measure of utility, typically a scale from 0 (death) to 1 (fully healthy) to each life-year 
gained. The unit of measurement this analysis creates is a ratio of dollars per quality-
adjusted life year (QALY). A QALY represents one year of life multiplied by some measure 
of utility, typically 0 (representing death) to 1 (representing fully healthy).5
Therefore a person who survives for 4 years at 0.75 utility gains 3 QALYs. This allows for 
comparison of a variety of interventions with different outcomes in a standardized way, 
using an incremental cost-effectiveness ratio (ICER), and also creates a patient-centered 
outcome, as it takes into account quality of life. Obviously, it is a complicated measure, so a 
disadvantage is the difficulty understanding the measurement. The generally accepted cutoff 
for what is considered cost-effective is $50,000 per QALY.11,12 This point of reference 
comes from the incremental cost-effectiveness ratio of dialysis, which is a federal 
entitlement to all citizens under Medicare.12 By that rationale, any intervention that is as 
cost-effective as dialysis should also be offered to all. Interventions with ICERs >$100,000 
per QALY are considered to be not cost-effective. Some authors believe that this number 
underestimates the acceptable costs to society, based on inflation and current accepted 
practices. One study suggested a range of $109,000 to $297,000 per QALY would be more 
in line with current societal preferences and inflation.13
Intensive Care Unit Costs
The intensive care unit consumes a large portion of hospital resources. Patients in the 
intensive care unit have longer lengths of stay and higher total costs than patients who never 
require ICU care.14 Recent estimates show that ICU care is responsible for 13.4% of 
hospital costs.1 When limited to Medicare beneficiaries, this number increases to almost 
one-third, while only 22% of Medicare hospitalizations require an ICU stay.14 The average 
ICU patient has a longer length of stay when compared to the hospitalized patient who never 
requires ICU care (7.8 days vs. 5.0 days). In the same study of Medicare recipients, the 
average total cost of hospitalization is much higher for patients who require an ICU stay 
than for those who never require ICU care ($14,135 vs. $5,571).14 Other studies have found 
slightly more variable costs, ranging from $14,135 to $32,253.4,14,15 Average daily costs in 
the ICU range from $2,278-$3518.1,14 However, using this analysis can be somewhat 
misleading, as multiple studies have demonstrated that the first ICU day is significantly 
more expensive than each subsequent day.4,7 As shown in Figure 1, the cost of the first ICU 
day was $7,728, while subsequent day costs were each less than $4,000. Patients who 
require ICU care also have a significant burden of illness after hospitalization. Another 
study of Medicare recipients examined patients who required an ICU stay, patients who 
were hospitalized but never required ICU care, and patients who were never hospitalized. 
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This study showed that the rate of hospitalization and use of skilled nursing facility (SNF) 
was slightly higher in the ICU group than in hospital controls, and significantly higher than 
the general population.16
Costs of Mechanical Ventilation
Patients requiring mechanical ventilation utilize an even larger portion of critical care 
medicine and hospital resources. Nearly 3% of hospitalized patients require mechanical 
ventilation, with an incidence of 2.7 episodes per 1000 population.3 At an estimated national 
cost of $27 billion, this represents nearly one-third of ICU costs. Mechanically ventilated 
patients accrue higher total costs than their non-ventilated counterparts. In 2005, a study 
conducted to determine the attributable costs of mechanical ventilation revealed longer mean 
lengths of stay (6.9 days vs. 2.9 days), higher total ICU costs ($31,574 vs. $12,931) and 
hospital costs ($47,158 vs. $23,707) and an incremental cost of $1,522 per patient per day.4 
However, this incremental cost reflected average daily total costs, rather than marginal or 
variable costs. Median costs were significantly lower than average costs for all patients in 
this same study, again demonstrating that ICU costs, including those of mechanically 
ventilated patients, are not likely to be normalized, but skewed by higher initial costs (Figure 
1). Moreover, it is important to remember that much of the cost associated with mechanical 
ventilation is reflective of their higher severity of illness when compared to their non-
ventilated counterparts. Comparing the cost of an ICU day liberated from mechanical 
ventilation to an ICU day of a patient who never required mechanical ventilation may not be 
a realistic comparison. Additionally, another study to evaluate the marginal costs of an ICU 
stay confirmed that over 80% of costs in the ICU are fixed hospital costs, which are incurred 
regardless of patient throughput.7 The contribution of direct-variable costs (i.e. costs that 
could potentially be reduced by a shorter length of stay or fewer interventions) was much 
smaller (see Table 2). For example, the direct-variable cost-reduction of liberating a patient 
from the ventilator was only $106. Transferring a patient from the ICU to the ward saved 
only $118.
Several studies have evaluated the cost-effectiveness of mechanical ventilation.15,17-20 
Incremental costs per QALY range from $11,970 to $110,000. Variations in costs can be 
variably ascribed to adjustments for age, comorbidities and prognosis. For example, the cost 
of providing mechanical ventilation to a patient with acute respiratory failure without pre-
existing lung disease was $11,970 per QALY, while the same provision to a patient with 
pre-existing lung disease was $14,365 per QALY.15
Prolonged mechanical ventilation (PMV) accounts for 5-10% of patients who require 
mechanical ventilation. PMV patients have a 1-year mortality of 50 to 60% in most 
studies.8,21,22 Economic evaluation of prolonged mechanical ventilation has been 
complicated in the past, given a wide variety of definitions for PMV. One study compared 
the costs of prolonged acute mechanical ventilation (PAMV), defined as 96 hours or greater, 
with mechanical ventilation for less than 96 hours (acute MV).23 Of over 750,000 patients 
requiring mechanical ventilation in 2003, 61% received it for less than 96 hours, while 39% 
received PAMV. Patients with PAMV, when compared to patients with acute MV, 
experienced longer length of stay (17 vs. 6 days) and higher median costs ($40,903 vs. 
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$13,434). Average daily costs were not statistically different between the groups ($2,666 for 
PAMV vs. $3,228 for MV). Total aggregate costs were over $16 billion for PAMV patients 
compared to only $9 billion for the acute MV group. Therefore, 39% of patients requiring 
mechanical ventilation account for 64% of hospital costs for mechanically ventilated 
patients. In-hospital mortality was similar in the two groups. PMV also contributes 
significantly to post-hospital costs. One study revealed that recipients of PMV spent nearly 
75% of the first year either in an LTAC, SNF, or receiving home health care.24 Two-thirds 
of these patients were readmitted to the hospital at least once after discharge. Mean costs per 
patient in this study were $306,135.
Fewer studies have analyzed the cost-effectiveness of prolonged mechanical ventilation. 
One study demonstrated even wider variation in cost-effectiveness in PMV than is seen 
during mechanical ventilation in general.18 This study utilized a base case patient, and 
defined PMV as mechanical ventilation for ≥21 days with placement of a tracheostomy. The 
comparison was the alternative of withdrawal of mechanical ventilation at some point 
between 7 and 21 days of mechanical ventilation. This study also examined post-hospital 
costs, which are typically much higher for patients that require mechanical ventilation. Total 
costs for care were $196,077 for PMV, compared to $52,269 for withdrawal of mechanical 
ventilation. Hospitalization accounted for $120,370 of this total for the PMV patient. 
Obviously, the withdrawal comparator incurred no post-hospital costs. Incremental costs 
were considerably higher for PMV compared to mechanical ventilation in general, with an 
overall ICER of $82,411 per QALY. The same increased costs held up when utilizing an 
alternative definition of PMV (mechanical ventilation for ≥4 days plus tracheostomy 
placement) with ICER of $73,629 per QALY. Using the same modeling, provision of 
mechanical ventilation for ≥2 days but <7 days incurred only $28,517 per QALY. Further 
broken down by age, providing PMV for an 18-year-old was associated with an ICER of 
only $14,289 per QALY, while the same provision for a 75-year-old incurred $127,589 per 
QALY, and an 85-year-old >$206,000 per QALY. When adjusted based on estimated 1-year 
survival, those with >50% survival would incur $60,967 per QALY, while those with <50% 
1-year survival incurred $101,787 per QALY.
Cost Differences Between ARDS and Other Critical Illness
Outcomes and costs of ARDS have been well-studied in a large cohort of patients. A series 
of articles has reported on one-, two-, and 5-year outcomes of hospital survivors of 
ARDS.25-27 The cohort was composed of 109 patients identified with ARDS, between 
1998-2002. Patients were followed prospectively for 1 year, then consented for further 
follow-up. The authors examined costs, including post-hospital costs, functional status, and 
work status. Average total hospital costs were $128,860 (2002 Canadian $), with the 
majority of this cost born in the ICU ($97,810). Of these costs, the largest contributor was 
nursing care, which accounted for over 75% of the costs incurred. Of survivors at 2 years, 
39% had been hospitalized, 20% more than once. Post-discharge costs were $28,350 by year 
two (2002 Can$), and totaled $49,572 by year 5 (2009 Can$). Figure 2 shows the post-
discharge costs. The first year after discharge was the most expensive, responsible for nearly 
half the 5-year total. Post-discharge costs varied significantly based on the number of 
coexisting illnesses. Patients with ≤1 coexisting illness incurred less than $40,000 by year 5, 
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while those with ≥2 coexisting illnesses incurred over $80,000. Average yearly post-hospital 
costs by year 5 were $5,566, which was fairly stable from the two years prior. This remains 
higher than the expected costs for healthy workers of between $1,100 and $3,200.
Consistent with the high costs of caring for ARDS survivors were their high degree of 
functional limitations. At one year, only 49% had returned to work.25 At two years, this 
number had increased to 65%.26 However, at 5 years, only 77% had ultimately returned to 
work.27 Of survivors with complete follow-up, 83% had been working prior to their critical 
illness. This study was not able to measure indirect costs (as discussed earlier, quite difficult 
to measure) but the increased costs of their health-care after their illness coupled with the 
lost wages of the patients and their families only serves to increase the burden of critical 
illness in these patients.
Another study evaluated the cost-effectiveness of mechanical ventilation for ARDS based on 
the SUPPORT trial. 20,28 In this study, they developed a model to determine the likelihood 
of survival, and stratified patients to low-risk (>70% estimated 2-month survival), medium-
risk (51-70% estimated 2-month survival), and high-risk (≤50% estimated 2-month 
survival). Total costs and cost-effectiveness both varied by likelihood of survival. Total 
costs were higher for medium-risk patient ($70,130) than for low-risk ($59,096) or high-
risk, $59,310. However, cost-effectiveness was directly proportional to risk. For low-risk 
ARDS patients, the ICER was $29,000 per QALY, for medium-risk patients, the ICER rose 
to $44,000 per QALY, and for high-risk patients, the ICER increased to $110,000 per 
QALY, beyond what is considered cost-effective. Such a small change in prognosis and 
survival had a tremendous impact on expected costs.
So how do these costs compare with other accepted medical treatments? Table 3 summarizes 
the incremental costs associated with various interventions, both in and out of the ICU. 
Mechanical ventilation for acute respiratory failure is as cost-effective as many other 
medical interventions. For example, mechanical ventilation for ARDS has similar cost-
effectiveness to the use of recombinant tissue plasminogen activator for acute stroke, 
therapeutic hypothermia for out-of-hospital cardiac arrest, percutaneous coronary 
intervention for stable angina, and cardiac resynchronization therapy for heart failure.29-32 
Prolonged mechanical ventilation may be cost effective when provided to younger patients 
with fewer comorbidities, and those whose expected survival is >50%. Prolonged 
mechanical ventilation is not cost-effective when provided to a patient with less than a 50% 
chance of survival. However, PMV still is less costly than CPR for in-hospital cardiac arrest, 
which boasts an ICER of $225,892 per QALY.33
Factors driving costs
There are many factors that contribute to the costs of ICU care and ARDS. Patients who 
require mechanical ventilation have higher severity of illness and a higher number of 
comorbidities than their non-mechanically ventilated counterparts.16 These patients also 
have higher lengths of stay, thus driving up total costs regardless of stable daily costs after 
the first two days.3,16,34,35 These patient factors are generally not modifiable, but do have a 
significant impact on costs.36 Insurance status, or more specifically the lack thereof, seems 
Bice et al. Page 6






















to result in decreased utilization of common ICU resources, e.g. tracheostomy, 
hemodialysis, and central venous catheters.37 This seemingly decreases costs, but is also 
associated with an increased risk of mortality. Unfortunately, the largest contributor to 
healthcare costs is hospital costs, and direct fixed costs comprise over 80% of these costs.7 
Changes in ICU length of stay will only modify these costs if the discharged patient is not 
replaced with a new patient in their stead. Over time, reductions in ICU length of stay could 
lead to a reduction in staffing needs, which could reduce costs, but this could have a 
negative impact on workforce. With the increasing utilization of ICU beds, it is unlikely that 
meaningful reduction in workforce costs could be achieved.
Implications for Practitioners and Policy-makers
What can be done about the costs of critical care? Quality improvement initiatives have 
demonstrated reductions in hospital acquired complications, which can reduce costs.38,39 
Multiple studies have demonstrated an improvement in catheter-related blood-stream 
infection rate when simple protocols were implemented.38-40 A recent study demonstrated 
that even potentially costly interventions to improve adherence to lung protective ventilation 
from 50 to 90% would be cost-effective, with an ICER of $11,690 per QALY.17 A hospital 
could spend over $9,000 per patient to implement better adherence, and this intervention 
remained cost-effective. Yet, despite these interventions, it remains true that the majority of 
costs in the intensive care unit remain fixed, and are resistant to such interventions. Modest 
reductions in days of mechanical ventilation, ICU length of stay, and even hospitalization 
are unlikely to yield significant cost reductions.
Despite this, many interventions in critical care have aimed at decreasing ICU and hospital 
length of stay. As an example of the potential flaws in this approach, one study 
demonstrated that the true cost reduction accomplished by reducing ICU length of stay by 
one day was only $118.7 This analysis may have underestimated attributable costs, though, 
as each day in the hospital increases the risk of hospital acquired complications, and 
nosocomial complications are more common in the ICU. Approximately 90% of nosocomial 
blood stream infections are associated with central venous catheters, which are more 
commonly placed in the intensive care unit.41 These complications incur additional costs 
and increase both ICU and hospital length of stay.42 In one study, adverse events were 
associated with an increase in ICU costs of $3,961.43 While reducing ICU length of stay 
may have an impact on the rate of complications, it is unclear what length of stay reduction 
translates into clinically meaningful reduction in these complications.
On the other hand, one method that many hospitals utilize to reduce length of stay and 
perhaps hospital costs is to discharge patients to long-term acute care hospitals (LTACs). 
There is significant incentive for hospitals to reduce length of stay, and therefore utilization 
of long-term acute care hospitals (LTACs) has been increasing.44,45 The Center for 
Medicaid and Medicare Services (CMS) stipulates that LTACs are required to have an 
average length of stay greater than 25 days for its Medicare recipients.46 LTACs are paid 
less for patients who stay < 5/6 of their average length-of-stay. This practice is likely to 
result in cost-shifting as opposed to true cost reduction, however. In fact, one study recently 
noted that the costs of total episode of illness for patients referred to LTACs were nearly 
Bice et al. Page 7






















50% higher than costs for similar patients not referred.47 This remained true regardless of 
the reason for initial admission. In patients requiring mechanical ventilation, the mean cost 
of care was $32,930. Length of stay was at least 20 days longer for the patients referred to 
an LTAC than for their matched counterparts. Reforming the payment structure for these 
typically for-profit post-acute care institutions represents a priority for cost-reduction 
measures.
The utilization of critical care services is increasing, and will continue to increase. The 
complexity of the patients cared for in the ICU is also increasing.35,44 Both the Leapfrog 
group and the Society of Critical Care Medicine have made recommendations regarding 
intensivist physician staffing of the ICU.48,49 Despite this, there remains a difficulty finding 
sufficient intensivist physicians to adequately meet these recommendations.50 Additionally, 
the possible benefit of 24-hour staffing of ICUs by intensivists remains unclear. One study 
has shown that there is no impact on mortality if the ICU is already staffed by an intensivist 
during the day.51 Another study demonstrated no impact on long-term survival or quality of 
life with the addition of a nighttime intensivist to an ICU in a teaching hospital.52 There 
remains inadequate data regarding the optimal number of ICU patients a single intensivist 
should provide care for or what is the best balance of intensivists and lower-cost physician 
extenders. Future studies identifying optimal staffing levels could aid in cost reduction 
through improved delivery of critical care.
Prolonged mechanical ventilation appears to be more costly than the provision of short-term 
mechanical ventilation, and appears to be a reasonable target for cost-reduction. The number 
of patients receiving PMV increased from around 250,000 in 2000 to over 375,000 in 2008, 
and is expected to be greater than 625,000 by the year 2020.53 Future interventions in the 
provision of prolonged mechanical ventilation, or the avoidance of PMV could lead to 
significant reductions in the costs of critical care. Yet, despite the high costs of PMV, a 
study of survivors of PMV found that 75.9% would choose to undergo mechanical 
ventilation based on their experiences.54 Recipients of Medicare were less likely to choose 
mechanical ventilation in this study. However, another study of surrogates found that an 
overwhelming majority reported receiving no information regarding aspects of PMV that 
they felt was important, including expected functional status (80%), quality of life (72%), 
cognitive status (65%), and services that might be needed after hospitalization (82%).55 
Another study demonstrated that there is significant discordance between clinicians and 
patients or their surrogates regarding expected outcomes of PMV.8 Both physicians and 
surrogates tended to be overly optimistic regarding potential outcomes. In that same study, 
only 11% of patients were alive and independently functioning at one year. A recently 
developed prognostic model can aid physicians in discussing potential outcomes with 
patients and their families.56 Further development of useful, timely, and broadly applicable 
prognostication tools and communication interventions, particularly when it comes to 
prolonged mechanical ventilation would be a potential method to reduce utilization of this 
costly intervention. Effective communication remains the ICU clinician’s best tool in 
addressing the appropriateness of ICU care.
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Evaluation of costs in the intensive care unit is a complicated endeavor. A variety of factors 
affect the costs of care. The provision of short-term mechanical ventilation for acute 
respiratory failure and ARDS is cost-effective by current societal standards. Continued focus 
on interventions to reduce duration of mechanical ventilation and ICU length of stay are 
clinically important, but may not yield significant cost reductions for the healthcare system. 
Prolonged mechanical ventilation may not be cost-effective, particularly when provided to 
those with worse prognoses. Improved development of prognostication models and 
increased effectiveness of communication between clinicians and patients or their surrogates 
could help avoid costly interventions with poor outcomes.
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Figure 1. Mean Daily ICU Cost
Adapted from Dasta et al4
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Figure 2. Post-discharge Costs of ARDS
*Costs in 2009 Canadian dollars
Adapted from Herridge et al27
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Table 1
Types of economic evaluations
Evaluation type BenefitMeasurement Result Advantages/Disadvantages
Cost-minimization
analysis None Cost Difference






- Dissimilar therapies and outcomes can be compared






- Evaluates for specific outcomes
- Cannot compare analyses between outcomes
Cost-utility analysis Healthy Cost per QALY
- Can compare different therapies with different outcome 
assessments, evaluates patient centered outcomes (e.g. quality of 
life)
- Can be challenging to understand
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Table 2




Direct-Variable† $12,773 (18.4% of total)
Average Daily Direct-Variable $1751
Marginal Direct-Variable‡ $649-$839
Direct-Variable difference
-- Last ICU day to first ward day
-- Last ventilator day and first non-ventilator day




Adapted from Kahn et al7
*
Total costs excluding overhead, but including staff salaries and equipment costs
†
Variable costs excluding staff salaries and equipment costs
‡
Cost of each additional day after day 2
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Table 3
Cost-Effectiveness of Selected Medical Interventions
Intervention Cost/QALY
Mechanical ventilation for respiratory failure
related to pneumonia or ARDS (1998 US$)20
$29,000 (estimated 2-month survival >70%)
$44,000 (estimated 2-month survival 51%-70%)
$110,000 (estimated 2-month survival ≤50%)
ICU care for patients with acute respiratory failure
without chronic lung disease (1996 US$)15
$11,970
ICU care for patients with acute respiratory failure
with chronic lung disease (1996 US$)15
$14,365
Integrated Sepsis treatment protocol for septic
shock(2004 US$)57
$16,309
Recombinant Tissue Plasminogen Activator in
Acute Stroke29,58
$29,148 to 55,591 (Short-term costs) (2009 US$)
−$41,137 to $4,662 (Long-term Health-care
benefits/costs) (2009 US$)
$6,255 (Patients between 3-4.5 hours) (2011 US$)
Lung transplantation compared to standard care
(1994 US$)59
$44,000 (assuming 10-year survival)
$204,000 (assuming 5-year survival)
Therapeutic hypothermia for out-of-hospital V-fib
arrest (2008 US$)30
$47,168
PCI plus OMT compared with OMT alone for
stable angina (2010)31
€24,805
CRT vs. ICD for heart failure (2008 US$)32 $58,330
$16,640 (subgroup with LBBB)
Prolonged mechanical ventilation (>21 days) after
acute illness (2005 US$)18
$82,411
$60,967 (estimated 1-year survival >50%)




PCI = Percutaneous coronary intervention, OMT = Optimal medical therapy, CRT = Cardiac resynchronization therapy, ICD = Implantable cardiac 
defibrillator, LBBB = Left bundle branch block
Semin Respir Crit Care Med. Author manuscript; available in PMC 2014 December 10.
